Recent developments in federal marijuana rescheduling center on the April 2026 Department of Justice order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while broader marijuana remains in Schedule I. A DEA administrative hearing on wider reclassification concluded in July 2026, with the chief administrative law judge now weighing testimony and post-hearing briefs filed in August. The DEA has argued in its final submission that marijuana meets criteria for accepted medical use and safety under supervision. A D.C. Circuit ruling on September 9 rejected efforts to stay the partial order amid ongoing litigation. Trader consensus on Polymarket reflects low implied probabilities for full rescheduling by year-end, citing the pending ALJ recommendation, potential court delays, and procedural hurdles before any DEA administrator decision.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено$809,958 Объем
30 сент. 2026 г.
30 сентября
2%
31 декабря
17%
$809,958 Объем
30 сентября
$679 Объем
2%
31 декабря
$199,708 Объем
17%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent developments in federal marijuana rescheduling center on the April 2026 Department of Justice order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while broader marijuana remains in Schedule I. A DEA administrative hearing on wider reclassification concluded in July 2026, with the chief administrative law judge now weighing testimony and post-hearing briefs filed in August. The DEA has argued in its final submission that marijuana meets criteria for accepted medical use and safety under supervision. A D.C. Circuit ruling on September 9 rejected efforts to stay the partial order amid ongoing litigation. Trader consensus on Polymarket reflects low implied probabilities for full rescheduling by year-end, citing the pending ALJ recommendation, potential court delays, and procedural hurdles before any DEA administrator decision.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Открытие рынка: Jul 31, 2026, 5:46 PM ET
Объем
$809,958Дата окончания
1 янв. 2027 г.Открытие рынка
Jul 31, 2026, 5:46 PM ETКто определяет исход
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent developments in federal marijuana rescheduling center on the April 2026 Department of Justice order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while broader marijuana remains in Schedule I. A DEA administrative hearing on wider reclassification concluded in July 2026, with the chief administrative law judge now weighing testimony and post-hearing briefs filed in August. The DEA has argued in its final submission that marijuana meets criteria for accepted medical use and safety under supervision. A D.C. Circuit ruling on September 9 rejected efforts to stay the partial order amid ongoing litigation. Trader consensus on Polymarket reflects low implied probabilities for full rescheduling by year-end, citing the pending ALJ recommendation, potential court delays, and procedural hurdles before any DEA administrator decision.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Объем
$809,958Дата окончания
1 янв. 2027 г.Открытие рынка
Jul 31, 2026, 5:46 PM ETКто определяет исход
0x65070BE91...Recent developments in federal marijuana rescheduling center on the April 2026 Department of Justice order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while broader marijuana remains in Schedule I. A DEA administrative hearing on wider reclassification concluded in July 2026, with the chief administrative law judge now weighing testimony and post-hearing briefs filed in August. The DEA has argued in its final submission that marijuana meets criteria for accepted medical use and safety under supervision. A D.C. Circuit ruling on September 9 rejected efforts to stay the partial order amid ongoing litigation. Trader consensus on Polymarket reflects low implied probabilities for full rescheduling by year-end, citing the pending ALJ recommendation, potential court delays, and procedural hurdles before any DEA administrator decision.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы